Generated by AI
Chemomab Therapeutics Ltd. American Depositary Shares is the publicly traded ADR representation of Chemomab Therapeutics Ltd., a clinical-stage biotechnology company focused on developing therapies for fibro-inflammatory diseases. The company’s work centers on antibody-based treatments designed to address conditions involving inflammation and fibrosis, with a primary emphasis on areas of high unmet medical need such as liver, skin, and lung disorders. Chemomab Therapeutics Ltd. operates as a research-driven biopharmaceutical business, advancing product candidates through clinical development and working to translate its science into potential disease-modifying treatments. Its market role is that of a specialized biotech issuer within the healthcare sector, giving investors access to a company centered on novel therapeutic research rather than commercial-scale drug sales. The asset name, Chemomab Therapeutics Ltd. American Depositary Shares, reflects its U.S.-traded structure while representing the company’s ordinary shares.
WebsiteBuilding C
Tel Aviv-Yafo, 6158101
Israel
The latest articles about CMMB.
Detailed price information for Chemomab Therapeutics Ltd ADR (CMMB-Q) from The Globe and Mail including charting and trades.
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)
Summary of Oct 30's posts. Generated by AI.
Summary of Jul 8's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Investors talking about CMMB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.